Table 1 Demographic and clinical landscape of 49 CRC patients
From: The role of PDGFRA as a therapeutic target in young colorectal cancer patients
| Â | Young CRC | Middle CRC | Old CRC |
|---|---|---|---|
Number | 13 | 23 | 13 |
Age |  <  = 40 | 41 – 60 |  > 60 |
Sex | |||
 Male | 5 (38.5%) | 8 (34.8%) | 10 (76.9%) |
 Female | 8 (61.5%) | 15 (65.2%) | 3 (23.1%) |
Tumor location | |||
 Colon | 9 (69.2%) | 19 (82.6%) | 12 (92.3%) |
 Rectum | 4 (30.8%) | 4 (17.4%) | 1 (7.7%) |
Cell differentiation | |||
 Adenocarcinoma | |||
  W/D | 2 (15.4%) | 1 (4.3%) | 3 (23.1%) |
  M/D | 10 (76.9%) | 18 (78.4%) | 9 (69.2%) |
  P/D | 0 (0%) | 3 (13.0%) | 0 (0%) |
 Mucinous carcinoma | 1 (7.7%) | 1 (4.3%) | 1 (7.7%) |
Stage | |||
 II | 2 (15.4%) | 6 (26.1%) | 1 (7.7%) |
 III | 4 (30.8%) | 2 (8.7%) | 3 (23.1%) |
 IV | 7 (53.8%) | 15 (65.2%) | 9 (69.2%) |
MSI status | |||
 MSS | 13 (100%) | 20 (87%) | 13 (100%) |
 MSI | 0 (0%) | 3 (13%) | 0 (0%) |